Survival analysis revealed that the group with a low NUSAP+ Glioma score and high TMB exhibited the most favorable survival outcomes, whereas the group with a high NUSAP+ Glioma score and low TMB showed the poorest prognosis (Figure 8J). This evidence concerns the gene NUSAP1 and central nervous system cancer.